DOCSLIB.ORG

DRUG DELIVERY Review and Outlook I N D U S T R Y G R O W T H T O C O N T I N U E T H R O U G H N E W Technologies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
DRUG DELIVERY Review and Outlook I N D U S T R Y G R O W T H T O C O N T I N U E T H R O U G H N E W Technologies SPECIAL REPORT DECEMBER 2011 DRUG DELIVERY REVIEW AND OUTLOOK INDUSTRY GROWTH TO CONTINUE THROUGH NEW TECHNOLOGIES The worldwide drug-delivery arena is growing each year as the increasing aging population is in need of improved methods of administration for products and therapies. Drug-delivery industry growth is being led by the United States as well as emerging markets. Oral forms remain the preferred method of drug-delivery administration. Gaining in popularity are parenteral, inhalation and implantable systems. Elements impacting the development of drug-delivery systems include reimbursement, environmental factors, and regulatory processes. Product developers are coming up with better ways to improve therapy performance and safety as patients become more involved in their treatments in an effort to cut down on costs. New electronic technologies for reusable systems and disposable devices are leading to improved sales of auto-injectors. Microneedle technology is on the rise so that medicine can be precisely delivered to areas in need of treatment. UBM CANON DATA PRODUCTS TABLE OF CONTENTS 828B Newtown-Yardley Road, Suite B Drug-Delivery Industry Overview . Page 3 Newtown, PA 18940 Drug-Delivery Company Overview . 8 United States Phone: +1 .215 .944 .9800 Drug-Delivery Prescription Products Fax: +1 .215 .867 .0053 Website: PharmaLive .com Awaiting Approval . 26 Steve Corrick Phase III . 29 VP and Executive Director UBM Canon Publishing Phase II/III . 36 steve .corrick@ubm .com Phase II . 37 Roger Burg Phase I/II . 46 VP, Operations Publications Division Phase I . 47 roger .burg@ubm .com +1 .310 .445 .4221 Preclinical Development . 50 Glenn Glasberg Companies . 52 Circulation and Marketing Director glenn .glasberg@ubm .com Drug-Delivery Medical Devices +1 .215 .944 .9810 Class I Devices – General Controls – 510(k) Exempt . 61 Sandra Baker Class II Devices – General Controls and Special Controls – 510(k) . 66 Data Products Manager sandra .baker@ubm .com Class III Devices – General Controls and Special Controls – 510(k) . 78 +1 .215 .944 .9836 Unclassified Devices – 510(k) . 79 Amanda Wells Assistant Marketing Manager Companies . 80 amanda .wells@ubm .com +1 .215 .944 .9840 Brandon Materazzi Marketing Assistant brandon .materazzi@ubm .com Review the most recent Special Reports at: www .PharmaLive .com/SpecialReports +1 .215 .944 .9809 Andrew Humphreys See these and other topics: Editor In Chief, Data Products andrew .humphreys@ubm .com POM Quarterly +1 .215 .944 .9812 Top 50 Specialty Companies Stefanie Fedder Global Contract Manufacturing Companies: Pharmaceutical and Biotechnology Manager, Data and Content stefanie .fedder@ubm .com Nutraceuticals and Vitamins Review and Outlook +1 .215 .944 .9807 Top 50 Pharmaceutical Companies and Their Pipelines John King Market Analyst/Editor john .king@ubm .com +1 .215 .944 .9820 eKnowledgeBase - searchable pipeline and business-information database for the world’s pharma & biotech companies . Request a trial at: www .PharmaLive .com/newEKB Silvia Arriola Data Specialist silvia .arriola@ubm .com +1 .215 .944 .9803 MDRWeb.com - searchable database of global medical device companies and Diane Strohm their products . Learn more at: www .MDRWeb .com - enter promo code SRTRIAL for Data Specialist diane .strohm@ubm .com free two-week trial access . +1 .215 .944 .9828 Andrew Ellison For more information on these products contact: Data Specialist andrew .ellison@ubm .com Sandra .Baker@ubm .com or call: +1-215-944-9836 +1 .215 .944 .9826 Stacey Miller Contributing editor EDITORIAL ADVISORS FOR SPECIAL REPOrtS Kim Stannard Jay Carter, SVP Director of Strategy Services, AbelsonTaylor Production assistant Sander Flaum, President, Flaum Partners Mark Havenhand, MBA, Ph .D ., Novartis Pharma AG, Global Head, UBM Ltd. Corporate Head Office Ludgate House Business Strategy & Planning Clinical Medical Services 245 Blackfriars Road Boaz Mendzelevski, VP of Cardiology & Chief Medical Officer, London, SE1 9UY, United Kingdom Medifacts International Phone: +44 (0) 20 7921 5000 Website: ubm .com Steven Michaelson, Managing Partner, RosettaWishbone Mike Myers, President, Palio UBM Canon Headquarters 11444 W . Olympic Blvd . David M. Oakley, R .Ph ., Ph .D ., Director of Technical Development, Los Angeles, CA 90064 AAIPharma United States Deborah Schnell, President, Sales and Strategic Planning, Phone: +1 .310 .445 .4200 Fax: +1 .310 .445 .4299 Healthy Advice Networks Website: ubmcanon .com Marc Weiner, Managing Partner, Ogilvy CommonHealth Worldwide 2 DruG DELIVERY REVIEW AND OUTLOOK The global drug-delivery market is ex- “There can be a cost benefit when health informatics in new patient-cen- periencing annual growth in the mid-to- transitioning health-care provision from tered systems,” he adds. high single digits. The rising global popu- the hospital environment to the home In the field of auto-injectors, sophisti- lation and the need for more convenient environment or other health-care facili- cated use of electronics in reusable sys- drug-administration methods have creat- ties,” he states. “Effective drug-delivery tems and disposable devices is causing ed more opportunities for manufacturers devices and systems that enable a patient growth, Mr. Reynolds says. to produce additional drug-delivery sys- to self-inject can aid this transition. For “There are also trends toward en- tems and therapies. example, it is now possible to transition hanced manual systems, including er- The U.S. drug-delivery market is an- from hospital IV to home-administered gonomic features designed to improve ticipated to generate 10 percent yearly subcutaneous injection through the use an impaired patient’s ability to deliv- growth during 2011 and 2012, according of an electronic patch injector or auto- er a dose from a prefilled syringe,” he to industry experts. injector.” states. “There are several well-estab- The worldwide pharma market was Auto-injectors are becoming more lished companies in this space offering projected to grow about 5-7% during commonly used to deliver medications device technologies, and increasing em- 2011 compared to 4-5% growth generat- that treat a variety of therapeutic areas phasis on new and merging players offer- ed in 2010. U.S. pharma sales were pre- such as rheumatoid arthritis, oncology, ing improved patient convenience, and dicted to be up slightly during 2011 com- diabetes, and multiple sclerosis. As a re- integration between the device and the pared to 2010. sult, mass production will be required to container.” The industry will continue to grow support the demand for auto-injectors through more sophisticated drug-deliv- and in turn stimulate various industrial MICRONEEDLE TECHNOLOGY ery systems, says Graham Reynolds, VP activities to support the manufacturing of Marketing/Innovation, Pharmaceutical processes required for development. In the realm of new technologies, a small Delivery Systems, West Pharmaceutical Worldwide sales of advanced drug-de- band of device-development companies Services Inc. “There will be an increase livery systems – inhalers, injections and have been attempting to commercialize in self-administration of therapies,” he infusion pumps – are projected to grow drug-delivery products based on arrays shares. “For novel devices, look for con- from a value of $139 billion in 2009 to of microneedles. By establishing chan- tinued trends toward safety and a strong $197 billion in 2014, according to Cam- nels in the outer most layer of the epi- focus on the needs of the patient.” bridge Design Partnership LLP experts. dermis, these devices were expected to West Pharmaceutical has developed Cambridge Design Partnership is a con- deliver therapeutic drugs across the skin innovative delivery systems such as the sulting company that develops drug-de- and into the dermal layers, according to ConfiDose auto-injector system and livery devices in the United Kingdom. Greystone Research Associates. the SmartDose electronic patch injec- Matt Schuman, senior partner at Cam- Greystone analysts say after years of tor. These systems offer a range of op- bridge Design Partnership, advises man- prototyping unique array designs, a few tions for dose volume, injection time and ufacturers to learn from other industries development programs have migrated electronic control/feedback. They are de- that focus on creating differentiation and toward improving the performance of signed to meet the challenges of innova- gaining competitive advantage through existing delivery methods. The market tive drug products. innovations in branding, usability and availability of microneedle drug-delivery Oral forms are expected to remain the shelf appeal. devices such as the Sanofi Pasteur’s In- largest drug-delivery category. Parenter- “We think, in the future, patients are tanza influenza vaccine, which is based al, inhalation and implantable systems going to be much more involved in their on Becton, Dickinson and Co.’s (BD) are on the quickest growth pace. Indus- own treatments to reduce costs and Soluvia syringe-mounted microneedle try analysts expect parenteral formula- smart drug-delivery technologies are part array device, is considered a milestone tions will eventually surpass oral dosag- of what is going to enable this change in the transition of microneedle drug de- es as the largest segment. safely,” says Tom Oakley, Head of Drug livery from development to market. Influencing drug-delivery systems de- Delivery at Cambridge Design Partner- Microneedle technology is anticipated velopment will be reimbursement,
Load more

Recommended publications
  • Formulation and Evaluation of Transdermal Patch and Gel of Nateglinide
    Human Journals Research Article September 2015 Vol.:4, Issue:2 © All rights are reserved by C. Aparna et al. Formulation and Evaluation of Transdermal Patch and Gel of Nateglinide Keywords: Nateglinide, transdermal patch and gel, HPMC, ethyl cellulose, carbopol, PVA, PVP ABSTRACT Anusha Gundeti, C. Aparna*, Dr. Prathima Srinivas The objective of the present work was to formulate Transdermal Drug Delivery systems of Nateglinide, an Department of Pharmaceutics, Sri Venkateshwara antidiabetic drug belonging to meglitinide class with a half life of 1.5 hrs. Transdermal patches containing nateglinide were College of Pharmacy, prepared by solvent casting method using the combinations Affiliated to Osmania University, of HPMC:EC, PVA:PVP, HPMC:Eudragit RS 100, Eudragit RL100:RS100 in different proportions and by incorporating Madhapur, Hyderabad, Telangana -500081, India. different permeation enhancers (polyethylene glycol 400, Su bmission: 7 September 2015 DMSO). The transdermal patches were evaluated for their physicochemical properties like thickness, weight variation, Accepted: 11 September 2015 folding endurance, percentage moisture absorption, percentage Published: 25 September 2015 moisture loss, in-vitro diffusion studies & ex-vivo permeation studies. Transdermal Gel was formulated using HPMC, carbopol 934, carbopol 940 and methyl cellulose. Gels were evaluated for homogeneity, pH, viscosity, drug content, in-vitro diffusion studies & ex-vivo permeation studies. By comparing the drug release F5 (HPMC:EC) formulation was selected as optimized formulation as it could sustain the drug release for 12 hrs i.e. 99.2% when compared to gel. Stability studies were www.ijppr.humanjournals.com carried out according to ICH guidelines and the patches maintained integrity and good physicochemical properties during the study period.
    [Show full text]
  • M Morpho of Sm Ologica Mall-Sp S Al, Phy Pore a Solana Siolog
    Vol. 8(37), pp. 3422-3434, 10 September, 2014 DOI: 10.5897/AJMR2014.6802 Article Number: B5A96EE47927 ISSN 1996-0808 African Journal of Microbiology Research Copyright © 2014 Author(s) retain the copyrighht of this article http://www.academicjournals.org/AJMR Full Length Research Paper Morphological, physiological and pathogenic variability of small-spore Alternaria sp. causinng leaf blight of Solanaceous plants in Allgeria BESSADAT Nabahat1*, SIMONEAU Philippe2, BENICHOU Soumaya1, SETTI Benali3, Kihal Mabrouk1 and HENNI Djamel Eddine1 1Laboratoire de Microbiologie Appliquée, Université d’Oran Es-Senia, BP15224 El M’naouer 31000 Oran, Algeria. 2SFR QUASAV 4207, UMR 1345 IRHS, Université d’Angers, 2 boulevard Lavoisier, France. 3Institut des Sciences Agronomiques, Université de Chlef, Algeria. Received 25 February, 2014; Acceppted 9 June, 2014 Due to premature defoliation, early blight epidemics can cause major yield losses. Large-spore Alternaria species such as A. solani and A. tomatophila have long been recognized as important pathogens responsible for such blight disease in the famiily Solanaceeae and thus represent a serious risk for crop production. Small-spore Alternaria species have also been frequently isolated from plant samples with typical blight symptoms but their incidence as primary pathogens is often controversial. In order to study the diversity of small-spore Alternaria species, 32 isolates were selected from a larger collection of 130 isolates from infected leaves, fruits and sttems of tomato from various growing regions of North-West Algeria. Morphological characterization under standard conditions annd polymerase chain reaction (PCR) analyses using specific primers to amplify a part of the ITS regions and the 5.8S gene were conducted to confirm their identification as members of the altternata section.
    [Show full text]
  • Migraine Specialty Care Program Tm
    MIGRAINE SPECIALTY CARE PROGRAM TM Phone: 833-796-6470 • Fax: 844-841-3401 Community Led Specialty Pharmacy Care 1 PATIENT INFORMATION: 2 PRESCRIBER INFORMATION: Name: ___________________________________________________ Name: ___________________________________________________ Address: _________________________________________________ Address: _________________________________________________ City: _________________________ State: ____ Zip: ____________ City: _________________________ State: ____ Zip: ____________ Phone: ___________________ Alt. Phone: ____________________ Phone: _____________________ Fax: _______________________ Email: ____________________________________________________ NPI: ________________________ DEA: _______________________ DOB: ___________ Gender: M F Caregiver: _____________ Tax I.D.: __________________________________________________ Height: ________ Weight: ________ Allergies: ________________ Office Contact: __________________ Phone: __________________ 3 STATEMENT OF MEDICAL NECESSITY: (Please Attach All Medical Documentation) Prior Failed Indicate Drug Name v10.0_060821 Length of Symptoms: ___________________________ ICD-10: _________________________ Treatments: and Length of Treatment: Other diagnosis _______________ Number of Migraine Days per month: ________________ Preventative: Headache Days per month: _________________ Migraine Hours per day: __________________ ACE-I/ARBs ___________________ Patient has been evaluated and does not have medication overuse headache? No Yes Antiepileptics ___________________
    [Show full text]
  • Create Low-Power Applications with MQX™ and MQX™ Lite RTOS FTF-SDS-F0040
    Hands-On Workshop: Create Low-Power Applications with MQX™ and MQX™ Lite RTOS FTF-SDS-F0040 Maclain Lobdell | Freescale Software Product Manager Vincent Leynaert | Freescale FAE APR.2014 TM External Use Hands-On Workshop: Create Low-Power Applications with MQX™ and MQX™ Lite RTOS FTF-SDS-F0040 4 Hour Class Learn how to take advantage of the power management capabilities of MQX and MQX Lite RTOS. See how to create feature-rich applications without killing battery life. Attendees will get hands-on experience with system power mode transitions, driver state transitions and slowing or stopping the system tick timer for power savings. TM External Use 1 Session Introduction • Power efficiency is an increasingly important part of embedded product design. Power consumption budgets are tightening even though performance expectations are ever increasing. • You can create power efficient applications while using an RTOS for sophisticated designs. TM External Use 2 Session Objectives • After completing this session you will be able to: − Understand how power management capabilities can be used in RTOS- based applications − Understand how to perform system power mode transitions, frequency scaling, driver state transitions, and slow or stop the RTOS system tick timer for power savings TM External Use 3 Agenda • Quick Review of MQX Software Solutions • Tools for Analyzing MCU Power • Kinetis MCU Low Power Features • MQX RTOS Power Management Features − Hands On • Optimizing Applications for Low Power − Optimizing/Disabling the System Tick Timer − Architecting
    [Show full text]
  • Cell Surface Mobility of GABAB Receptors Saad Bin
    Cell surface mobility of GABAB receptors Saad Bin Hannan September 2011 A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy of the University College London Department of Neuroscience, Physiology, and Pharmacology University College London Gower Street London WC1E 6BT UK Declaration ii ‘I, Saad Hannan confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis.' ____________________ Saad Hannan September 2011 To Ammu, Abbu, Polu Abstract ivi Abstract Type-B γ-aminobutyric acid receptors (GABABRs) are important for mediating slow inhibition in the central nervous system and the kinetics of their internalisation and lateral mobility will be a major determinant of their signalling efficacy. Functional GABABRs require R1 and R2 subunit co-assembly, but how heterodimerisation affects the trafficking kinetics of GABABRs is unknown. Here, an α- bungarotoxin binding site (BBS) was inserted into the N-terminus of R2 to monitor receptor mobility in live cells. GABABRs are internalised via clathrin- and dynamin- dependent pathways and recruited to endosomes. By mutating the BBS, a new technique was developed to differentially track R1a and R2 simultaneously, revealing the subunits internalise as heteromers and that R2 dominantly-affects constitutive internalisation of GABABRs. Notably, the internalisation profile of R1aR2 heteromers, but not R1a homomers devoid of their ER retention motif (R1ASA), is similar to R2 homomers in heterologous systems. The internalisation of R1aASA was slowed to that of R2 by mutating a di-leucine motif in the R1 C-terminus, indicating a new role for heterodimerisation, whereby R2 subunits slow the internalization of surface GABABRs.
    [Show full text]
  • DDT Cover/Back April 2006.Qx
    March 2007 Vol 7 No 3 www.drugdeliverytech.com IN THIS ISSUE INTERVIEW WITH DPT’S PRESIDENT MR. PAUL JOHNSON In Situ Gel Systems 30 Mitan Gokulgandhi, BPharm Dharmesh M. Modi, MPharm COX-II Microspheres 38 Lakshmi Sivasubramanian Madhumathi Seshadri Undermining CEO’s 82 John A. Bermingham FEATURING Parkinson’s Disease 59 Steven Damon Yogi R. Patel The science & business of specialty pharma, biotechnology, and drug delivery Specialty Pharma Indices 64 Dr. Barath Christopher Avani Amin, Josef Bossart, PhD Shankar Robinson, PhD Drug Delivery’s PhD Current Status of Clinical Trials Increasing New Ways to Non-Invasive In Asia 68 Importance to Partner With Insulin Delivery Ames Gross, MBA Big Pharma & the Federal Technologies Specialty Pharma Government Momoko Hirose March 2007 Vol 7 No 3 PUBLISHER/PRESIDENT Ralph Vitaro EXECUTIVE EDITORIAL DIRECTOR Dan Marino, MSc [email protected] CREATIVE DIRECTOR Shalamar Q. Eagel CONTROLLER Debbie Carrillo CONTRIBUTING EDITORS Cindy H. Dubin Debra Bingham Jason McKinnie TECHNICAL OPERATIONS Mark Newland EDITORIAL SUPPORT Nicholas D. Vitaro ADMINISTRATIVE SUPPORT Kathleen Kenny Corporate/Editorial Office 219 Changebridge Road, Montville, NJ 07045 Tel: (973)299-1200 Fax: (973) 299-7937 www.drugdeliverytech.com Advertising Sales Offices East & Midwest Victoria Geis - Account Executive Cheryl S. Stratos - Account Executive 103 Oronoco Street, Suite 200 Alexandria, VA 22314 Tel: (703) 212-7735 Fax: (703) 548-3733 E-mail: [email protected] E-mail: [email protected] West Coast Warren
    [Show full text]
  • Pharmacological Agents Currently in Clinical Trials for Disorders in Neurogastroenterology
    Pharmacological agents currently in clinical trials for disorders in neurogastroenterology Michael Camilleri J Clin Invest. 2013;123(10):4111-4120. https://doi.org/10.1172/JCI70837. Clinical Review Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in understanding the mechanisms of these disorders, through basic and translational research, and in targeting the receptors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients’ symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastroparesis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain. Find the latest version: https://jci.me/70837/pdf Review Pharmacological agents currently in clinical trials for disorders in neurogastroenterology Michael Camilleri Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota, USA. Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in under- standing the mechanisms of these disorders, through basic and translational research, and in targeting the recep- tors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients’ symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastropa- resis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain.
    [Show full text]
  • Medication Permission Form
    CHARDON LOCAL SCHOOLS MEDICATION PERMISSION FORM Student Name :__________________________________________ Grade/Class _______ Teacher :______________________ School ____________________ Student Address:____________________________________________________________________________ Date of Birth____________________________ TO BE COMPLETED BY HEALTH CARE PROVIDER Please print clearly and complete ALL sections. Time/Frequency Adverse Reaction to Report to (Include minimum time Physician and/or Special Name of Medication Dose Route (circle) Interval for prn dosing) Reason for Medication Start Date Stop Date Instructions Tablet/Capsule PO Liquid PO _________________ __/__/__ ___/___/___ Inhaler/Nebulizer OR OR Other__________ As needed every __hrs. ___ End of School year Tablet/Capsule PO Liquid PO _________________ __/__/__ ___/___/___ Inhaler/Nebulizer OR OR Other__________ As needed every __hrs ___ End of School year EPINEPHRINE AUTOINJECTOR Not Applicable SELF -CARRY AUTHORIZATION Yes, as the prescriber I have determined that this student is capable of possessing and using this autoinjector appropriately and have provided the student with training in the proper use of the autoinjector. ASTHMA INHALER Not Applicable SELF -CARRY AUTHORIZATION Yes, as the prescriber I have determined that this student to capable of possessing and using this inhaler appropriately and have provided the student with training in the proper use of the inhaler. Reminder note for prescriber: ORC 3313.718 requires backup epinephrine autoinjector and best practice recommends backup asthma inhaler Health Care Provider Name _______________________________________ Health Care Provider Signature: ______________________________________ Date_________________ Phone Number: _______________________________________ Fax Number: _________________________________________ TO BE COMPLETED BY PARENT OR GUARDIAN I authorize an employee of the school board to administer the above medication. I understand that additional parent/prescriber signed statements will be necessary if the dosage of medication is changed.
    [Show full text]
  • The Battle of Sailor's Creek
    THE BATTLE OF SAILOR’S CREEK: A STUDY IN LEADERSHIP A Thesis by CLOYD ALLEN SMITH JR. Submitted to the Office of Graduate Studies of Texas A&M University in partial fulfillment of the requirements for the degree of MASTER OF ARTS December 2005 Major Subject: History THE BATTLE OF SAILOR’S CREEK: A STUDY IN LEADERSHIP A Thesis by CLOYD ALLEN SMITH JR. Submitted to the Office of Graduate Studies of Texas A&M University in partial fulfillment of the requirements for the degree of MASTER OF ARTS Approved by: Chair of Committee, Joseph Dawson Committee Members, James Bradford Joseph Cerami Head of Department, Walter L. Buenger December 2005 Major Subject: History iii ABSTRACT The Battle of Sailor’s Creek: A Study in Leadership. (December 2005) Cloyd Allen Smith Jr., B.A., Slippery Rock University Chair: Dr. Joseph Dawson The Battle of Sailor’s Creek, 6 April 1865, has been overshadowed by Lee’s surrender at Appomattox Court House several days later, yet it is an example of the Union military war machine reaching its apex of war making ability during the Civil War. Through Ulysses S. Grant’s leadership and that of his subordinates, the Union armies, specifically that of the Army of the Potomac, had been transformed into a highly motivated, organized and responsive tool of war, led by confident leaders who understood their commander’s intent and were able to execute on that intent with audacious initiative in the absence of further orders. After Robert E. Lee’s Army of Northern Virginia escaped from Petersburg and Richmond on 2 April 1865, Grant’s forces chased after Lee’s forces with the intent of destroying the mighty and once feared iv protector of the Confederate States in the hopes of bringing a swift end to the long war.
    [Show full text]
  • An Archetype Swing in Transdermal Drug Delivery
    Indo American Journal of Pharmaceutical Research, 2017 ISSN NO: 2231-6876 A COMPREHENSIVE REVIEW ON MICRONEEDLES - AN ARCHETYPE SWING IN TRANSDERMAL DRUG DELIVERY G. Ravi*, N. Vishal Gupta, M. P. Gowrav Department of Pharmaceutics, JSS College of Pharmacy, JSS University, Shri Shivarathreeshwara Nagara, Mysuru, Karnataka, India. ARTICLE INFO ABSTRACT Article history Transdermal drug delivery is the non-invasive delivery of medications through the skin Received 23/12/2016 surface into the systemic circulation. The advantage of transdermal drug delivery system is Available online that it is painless technique of administration of drugs. The advantage of transdermal drug 31/01/2017 delivery system is that it is painless technique of administration of drugs. Transdermal drug delivery system can improve the therapeutic efficacy and safety of the drugs because drug Keywords delivered through the skin at a predetermined and controlled rate. Due to the various Microneedles, biomedical benefits, it has attracted many researches. The barrier nature of stratumcorneum Hypodermic Needles, poses a danger to the drug delivery. By using microneedles, a pathway into the human body Transdermal, can be recognized which allow transportation of macromolecular drugs such as insulin or Stratumcorneum, vaccine. These microneedles only penetrate outer layers of the skin, exterior sufficient not to Patch. reach the nerve receptors of the deeper skin. Thus the microneedles supplement is supposed painless and reduces the infection and injuries. Researches from the past few years showed that microneedles have emerged as a novel carrier and considered to be effective for safe and improved delivery of the different drugs. Microneedles development is created a new pathway in the drug delivery field.
    [Show full text]
  • Transdermal Nicotine Maintenance Attenuates the Subjective And
    Neuropsychopharmacology (2004) 29, 991–1003 & 2004 Nature Publishing Group All rights reserved 0893-133X/04 $25.00 www.neuropsychopharmacology.org Transdermal Nicotine Maintenance Attenuates the Subjective and Reinforcing Effects of Intravenous Nicotine, but not Cocaine or Caffeine, in Cigarette-Smoking Stimulant Abusers 1 1 ,1,2 Bai-Fang X Sobel , Stacey C Sigmon and Roland R Griffiths* 1Department of Psychiatry and Behavioral Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA; 2Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA The effects of transdermal nicotine maintenance on the subjective, reinforcing, and cardiovascular effects of intravenously administered cocaine, caffeine, and nicotine were examined using double-blind procedures in nine volunteers with histories of using tobacco, caffeine, and cocaine. Each participant was exposed to two chronic drug maintenance phases (21 mg/day nicotine transdermal patch and placebo transdermal patch). Within each drug phase, the participant received intravenous injections of placebo, cocaine (15 and 30 mg/70 kg), caffeine (200 and 400 mg/70 kg), and nicotine (1.0 and 2.0 mg/70 kg) in mixed order across days. Subjective and cardiovascular data were collected before and repeatedly after drug or placebo injection. Reinforcing effects were also assessed after each injection with a Drug vs Money Multiple-Choice Form. Intravenous cocaine produced robust dose-related increases in subjective and reinforcing effects; these effects were not altered by nicotine maintenance. Intravenous caffeine produced elevations on several subjective ratings; nicotine maintenance did not affect these ratings. Under the placebo maintenance condition, intravenous nicotine produced robust dose-related subjective effects, with maximal increases similar to the high dose of cocaine; nicotine maintenance significantly decreased the subjective and reinforcing effects of intravenous nicotine.
    [Show full text]
  • Instructions For
    Instructions for Use Please see page 2 Instructions for Use Please see page 3 SIMPONI® (SIM-po-nee) (golimumab) SIMPONI® (SIM-po-nee) (golimumab) SmartJect® autoinjector Prefilled Syringe SINGLE-DOSE Important Important If your doctor decides that you or a caregiver may be able to give your SIMPONI® injections at home, you should SIMPONI® comes as a single-dose prefilled syringe containing one 50 mg or one 100 mg dose. Each SIMPONI® prefilled receive training on the right way to prepare and inject SIMPONI® using SmartJect®. syringe can only be used one time. Throw away (dispose of) the used prefilled syringe (See Step 3) after one dose, even Do not try to inject SIMPONI® yourself until you have been shown the right way to give the injections by your doctor if there is medicine left in it. Do not reuse your SIMPONI® prefilled syringe. or nurse. If your healthcare provider decides that you or a caregiver may be able to give your injections of SIMPONI® at home, Please read this Instructions for Use before using SIMPONI® SmartJect® and each time you get a refill. There may be you should receive training on the right way to prepare and inject SIMPONI® using the prefilled syringe before new information. This leaflet does not take the place of talking with your doctor about your medical condition or attempting to inject. Do not try to inject yourself until you have been shown the right way to give the injections by your your treatment. healthcare provider. Read this Instructions for Use before using your SIMPONI® prefilled syringe and each time you get a refill.
    [Show full text]